SRX Global Signs Definitive Agreement to Acquire CERo Therapeutics

Key Facts

1SRX Global entered into a definitive purchase agreement to acquire CERo Therapeutics as a wholly-owned subsidiary.

2The acquisition will be executed via a Special Purpose Vehicle (SPV) to avoid diluting existing SRX Global shareholders.

SRX Global entered into a definitive purchase agreement to acquire CERo Therapeutics as a wholly-owned subsidiary, GlobeNewswire reported. The acquisition will be executed via a Special Purpose Vehicle (SPV) named CERO 1236, a structure designed to avoid diluting existing SRX Global shareholders.

The transaction aims to accelerate the development of CERo's lead product candidate, CER-1236, for the treatment of hematologic malignancies. CERO closed at $0.00925 on October 6, 2026, having reached a day high of $0.0105 and a low of $0.00925 during that session.